Evidence map›Paper›PMID 31431707›Full record

ArticleBone marrow transplantation2019

ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL.

Patrick Schlegel, Gundram Jung, Anne-Marie Lang, Michaela Döring, Johannes H Schulte, Martin Ebinger, Ursula Holzer, Florian Heubach, Christian Seitz, Barbara Lang and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Patrick SchlegelDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Gundram JungDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tuebingen, Germany.
Anne-Marie LangDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Michaela DöringDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Johannes H SchulteDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Martin EbingerDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Ursula HolzerDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Florian HeubachDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Christian SeitzDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Barbara LangDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Patrick HundsdörferDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Angelika EggertDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Charité Berlin, Germany.
Thomas EichholzDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
Hermann KreyenbergDepartment for Stem Cell Transplantation and Immunology, Clinic for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.
Peter Lang *Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany. peter.lang@med.uni-tuebingen.de.
Rupert Handgretinger *Department of Pediatric Hematology and Oncology, University Children's Hospital, University of Tuebingen, Tuebingen, Germany.
University Children's Hospital Tübingen · DECharité - Universitätsmedizin Berlin · DEGoethe University Frankfurt · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posttransplant relapsed B-cell precursor ALL can be cured by 2nd hematopoietic stem cell transplantation (HSCT) in 20% of patients. The major cause of death after second HSCT is leukemic relapse. One reliable predictor for survival after 2nd-HSCT are posttransplant MRD levels. Patients with detectable or increase of MRD are likely to relapse. Patients in complete molecular remission show the best leukemia-free survival and lowest cumulative incidence (CI) of relapse. As patients who undergo second or subsequent HSCT are high-risk patients, we evaluated the prophylactic use of the chimeric Fc-optimized CD19-4G7SDIE-mAb. Posttransplant relapsed CD19

Indexed as

AdolescentAntibody-Dependent Cell CytotoxicityChildChild, PreschoolCohort StudiesDisease-Free SurvivalFemaleGraft vs Leukemia EffectHematopoietic Stem Cell TransplantationHumansLeukemiaTransplantation ConditioningTreatment Outcome

Identifiers

PMID31431707
OpenAlexW2969471705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.